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Background
Schnitzler’s syndrome (SchS) is an adult-onset autoinflam-
matory disease characterized by urticarial exanthema and
monoclonal gammopathy in combination with episodes of
fever, arthralgia, fatigue, and bone and muscle pain. Anti-
IL-1 targeting therapies in small patient numbers showed
to be effective in reducing the clinical symptoms of SchS.
Methods
The current placebo-controlled multi-center study was
designed to assess the effects of the anti-IL-1ß monoclonal
antibody canakinumab (CAN) on the clinical signs and
symptoms of SchS. We randomly assigned 20 patients
with active disease to receive CAN 150 mg or placebo s.c.
injections (day 0). Following the evaluation of treatment
responses on day 7 the study was continued by a 16-week
open label phase with CAN injections upon confirmed
relapse of clinical symptoms. Efficacy was determined by
changes in the physician’s global assessment (PGA; range
0-20), a combined symptom score which includes 5 key
symptoms of SchS (urticarial rash, fever, fatigue, myalgia
and arthralgia/bone pain), measurement of the inflamma-
tion markers C-reactive protein (CRP) and serum amyloid
A (SAA) as well as changes in quality of life assessment
(DLQI, SF-36).
Results
CAN was highly effective in reducing median PGA total
scores (14.0 to 2.0) as compared to placebo treatment
(15.0 to 13.0) within 7 days after first administration
(changes between treatment groups p < 0.0001). Median
CRP reduced from 9.3mg/dL at baseline to 0.6mg/dL at
day 7 in the CAN group vs. increase from 3.0mg/dL to
5.0mg/dL for the placebo group. Similarly, median SAA
levels reduced from 428mg/L to 13mg/L for the CAN
group vs. increase from 160mg/L to 205mg/L for the pla-
cebo group. The median changes from baseline to day 7
between treatment groups for CRP (p = 0.002) and SAA
(p = 0.032) were significant. In addition, quality of life
markedly improved. Changes in both physical component
SF-36 scores and in DLQI sum scores were significantly
greater (p < 0.0001) in the CAN vs. placebo group. The
clinical and laboratory improvements were maintained
during the open label phase of the study. Also, all pla-
cebo-treated patients responded well to CAN therapy
during the open-label phase. Adverse events were man-
ageable and included respiratory tract infections, gastro-
intestinal symptoms and hypertension.
Conclusion
In this placebo-controlled study, CAN s.c. injections sig-
nificantly improved the clinical signs and symptoms of
SchS, reduced inflammation markers, and enhanced qual-
ity of life. CAN treatment may be considered a promising
therapeutic option in these patients.
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